Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[212Pb]Pb-ADVC003
- Development stage
- Preclinical
- Lead developer
- Advancell
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Beta-minus Emitters → Radiopharmaceuticals, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Parenteral (likely Intravenous)
01
Overview
[212Pb]Pb-ADVC003 is a targeted alpha radioligand therapy under preclinical development by AdvanCell Isotopes for the treatment of cancers, specifically breast and pancreatic cancer. The drug utilizes the radioisotope lead-212 (²¹²Pb), which emits alpha particles to deliver ionizing radiation directly to tumor cells, aiming to maximize tumor cell kill while minimizing damage to surrounding healthy tissue. This approach leverages AdvanCell’s proprietary technology for reliable supply and conjugation of lead-212, enabling next-generation radiopharmaceuticals for oncology indications[1][2][9]. The mechanism of action is based on the emission of ionizing radiation from the radioactive isotope, resulting in DNA damage and subsequent cell death in targeted cancer cells[1][2].
Beyond the preview
Go deeper on [212Pb]Pb-ADVC003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [212Pb]Pb-ADVC003.